Kenneth Grossmann, MD
Medical Oncology · Salt Lake City, UTNPI 1083827455
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,250 of the $14,719 with a category attached, or 83.2%. 7 manufacturers reported payments, led by Novartis at 48.7% of the total. Reporting peaked in 2020 at $7,175 and has fallen 99.2% since, to $61 in 2025.
Across 37 payments — averaging $397.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- E.r. Squibb & Sons, L.L.C.$5K
- Pfizer$2K
- Incyte Corporation$280
- Clinigen, Inc.$145
- Merck$105
- plus $24 from 1 others
Across 55 payments — averaging $16,658 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$561K
- E.r. Squibb & Sons, L.L.C.$210K
- Regeneron$78K
- Genentech, Inc.$49K
- Exelixis Inc.$18K
- Novartis$140
What the payments were for
- Consulting fees$12,25083%
- Travel & lodging$1,3709%
- Food & beverage$1,0997%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $7,175 |
| E.r. Squibb & Sons, L.L.C. | 8 | $5,339 |
| Pfizer | 1 | $1,650 |
| Incyte Corporation | 19 | $280 |
| Clinigen, Inc. | 1 | $145 |
| Merck | 2 | $105 |
| Amgen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,719 in reported general payments places this provider in the 65th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 12 | $168 |
| Dexamethasone | 23 | $77 |
| Olanzapine | 25 | $37 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Salt Lake City
- Bradley HunterSalt Lake City$263K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
- Nitin ChandramouliSalt Lake City$19K
- Manish KohliSalt Lake City$13K
- Peter HaleSalt Lake City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.